3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Endocrine
2
Conditions
Adrenal Gland Neoplasms
4
Pheochromocytoma
2
Adrenal incidentaloma
2
Urinary Bladder Neoplasms
1
Hypokalemia
1
Hypertension
1
Hyperaldosteronism
1
Cushing Syndrome
1
Carcinoma, Renal Cell
1
Adrenocortical Carcinoma
1
Adrenocortical Adenoma
1
Interventions
3-Iodobenzylguanidine
8
anlotinib
4
Temozolomide
4
lutetium Lu 177 dotatate
3
Phenoxybenzamine
3
Everolimus
3
pegfilgrastim
2
cabozantinib
2
Granulocyte Colony-Stimulating Factor
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Adrenalectomy
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
vandetanib
1
temsirolimus
1
pentetreotide
1
penpulimab
1
pembrolizumab
1
olaparib
1
lenvatinib
1
lanreotide
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Pheochromocytoma
×
Adrenalectomy
×
Clear all
NCT07200245
2025-10-01
HEMODYNAMICS
Central Hospital, Nancy, France
Not yet recruiting
522 enrolled
NCT06062082
2025-02-13
HEMODADRE
Central Hospital, Nancy, France
Completed
60 enrolled